Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thymosin beta 4, X-linked pseudogene 3 (TMSB4XP3) is classified as a human pseudogene, indicated as such by authoritative databases[2][3][4][7][8]. Pseudogenes are segments of DNA that resemble functional genes but are typically noncoding and considered non-functional because they do not produce an active protein product. TMSB4XP3 is related in sequence to the functional TMSB4X gene, which encodes thymosin beta-4, a protein with important cellular roles, but the pseudogene variant itself does not encode a functional protein. There is no evidence TMSB4XP3 acts as a receptor, enzyme, signaling molecule, or therapeutic target. Its biological and clinical significance, if any, remains uncharacterized, and it is not implicated in any specific diseases or therapeutic modalities[2][3][4][6][7]. Clarification: This entry is a pseudogene and not a functional molecule or therapeutic target. Any research or clinical applications are related to the functional TMSB4X gene or thymosin beta-4 protein, not TMSB4XP3[5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thymosin beta 4, X-linked pseudogene 3 (TMSB4XP3).